← Eichor
Study identifier: NCT07614997 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effectiveness and Safety of the Ulthera® System for Skin Laxity in the Lower Face, Submentum and Neck

Condition: Cutis Laxa  ·  Sponsor: Merz North America, Inc.

PhaseNA
Planned participants218
Who can joinAll sexes, 35 Years to 65 Years
Healthy volunteersYes

About this study

The purpose of this study is to demonstrate superiority of treatment with the Ulthera System compared to untreated control for the improvement of skin laxity of the lower face, submental area and neck and to demonstrate the safety of treatment with the Ulthera System for the improvement of skin laxity of the lower face, submental area and neck.

This description comes directly from the study's public registry record.

Talk to the study team

Public Disclosure Manager Merz Aesthetics  ·  +1 984-301-3095  ·  Aesthetic.Trials@merz.com

Always discuss trial participation with your own doctor first.

Locations (7)

Merz Investigative SiteBeijing, Beijing Municipality, ChinaRecruiting
Merz Investigative SiteBeijing, Beijing Municipality, ChinaRecruiting
Merz Investigative SiteGuangzhou, Guangdong, ChinaRecruiting
Merz Investigative SiteNanjing, Jiangsu, ChinaRecruiting
Merz Investigative SiteXi'an, Shaanxi, ChinaRecruiting
Merz Investigative SiteShanghai, Shanghai Municipality, ChinaRecruiting
Merz Investigative SiteShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07614997